Pediatric Renal Transplantation: Protocols and Controversies

Leonard Curtis Hymes, MD (Editor)
Department of Pediatrics, Brody School of Medicine, NC, US

Series: Renal, Metabolic and Urologic Disorders
BISAC: MED088000



Volume 10

Issue 1

Volume 2

Volume 3

Special issue: Resilience in breaking the cycle of children’s environmental health disparities
Edited by I Leslie Rubin, Robert J Geller, Abby Mutic, Benjamin A Gitterman, Nathan Mutic, Wayne Garfinkel, Claire D Coles, Kurt Martinuzzi, and Joav Merrick


Digitally watermarked, DRM-free.
Immediate eBook download after purchase.

Product price
Additional options total:
Order total:



The role of immunosuppression is essential to maintain the integrity of a renal transplant by preventing acute rejection. Among adult patients with solid organ transplants, standard immunosuppression does not vary among the major transplant centers in the USA and Europe, and consists of corticosteroids, calcineurin inhibitors and mycophenolic acid. However, children with renal transplants are more susceptible than adults to suffer adverse events related to this standard protocol, including short stature, nephrotoxicity, lymph proliferative disease and infections. For this reason, pediatric nephrologists have explored alternatives to standard immunosuppression while still maintaining acceptable graft outcomes.

This book will explore this theme, which will include several chapters that present alternative immunosuppression protocol, in addition to other chapters that address challenging and controversial issues in pediatric renal transplantation. The first three chapters will describe immunosuppression protocols which may have specific benefits in children with renal allografts compared to standard regimens in adults. This includes the use of steroid-avoidance, which obviates many of the problems associated with corticosteroid use in children especially short stature and obesity. Secondly, the mTOR inhibitor Sirolimus is thoroughly discussed, including the potential benefits of this agent because of its lack of nephrotoxicity and possible anti-neoplastic properties. Lastly, induction therapy with Alemtuzumab is described, including recent studies that suggest that this agent may have definite benefits in children compared to standard induction with anti-thymocyte globulin.
(Imprint: Nova Biomedical)


Chapter I - Steroid Avoidance Protocols in Pediatric Kidney Transplantation (pp. 1-26)
Orly Haskin, M.D. and Paul C. Grimm, M.D. (Division of Nephrology, Department of Pediatrics, Stanford University School of Medicine, CA, US)

Chapter II - Sirolimus in Pediatric Renal Transplantation (pp. 27-56)
Belde Kasap, M.D. (Ýzmir Katip Çelebi University, School of Medicine, Department of Pediatrics, Division of Pediatric Nephrology, Ýzmir-Turkey)

Chapter III - Alemtuzumab: The Third Agent (pp. 57-66)
Leonard C. Hymes, M.D. (Brody School of Medicine, East Carolina University, Greenville, NC, US and others)

Chapter IV - BK-Polyomavirus Associated Nephritis (pp. 67-98)
Jennifer A. Jackson, M.D. (University of Kentucky, Kentucky Children's Hospital, Pediatric Nephrology& Renal Transplant Division, KY, US)

Chapter V - Protocol Biopsies in Pediatric Renal Transplant Recipients (pp. 99-116)
Patricia E. Birk, M.D., FRCP(C), Medical Director (Pediatric Kidney Program-Transplant Manitoba, Children’s Hospital, Health Sciences Centre, Winnipeg, MB, Canada)

Chapter VI - Adherence in the Pediatric Kidney Transplant Recipient (pp. 117-136)
Hilda Fernandez, M.D., MSCE and Sandra Amaral, M.D., MHS (The Children’s Hospital of Philadelphia, PA, US)


Audience: Pediatric Nephrologists, Transplant pharmacologists and immunologists

You have not viewed any product yet.